Dr Reddys Laboratories Thursday said itgot approval for selling generic Clopidogrel in China.

According to a clarification given to stock exchanges, the city-based drug maker said sales of this drug would not be materialised in the current financial year.

"Please note that the Company has received approval for the product Clopidogrel in China.

The Company believes that the sales from this product will not be material in the current financial year i.e. FY2020," DR Reddys said.

Clopidogrel is used to prevent heart attacks and strokes in persons with cardiovascular diseases.

Dr Reddy's shares closed at Rs 2930 apiece on BSE up 2061 per cent over previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)